ArticleFrontiers in microbiology2014
The habits of highly effective phages: population dynamics as a framework for identifying therapeutic phages.
Article in Frontiers in microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 79 citations in OpenAlex.
- PRISM: A unified platform for phage isolation and characterization from single-droplet microenvironments.Science advances · 2026Article
- Whole-Genome Sequencing and Functional Characterization of a NovelInternational journal of molecular sciences · 2025Article
- Navigating the Fitness Landscape: Host Density, Epistasis, and Clonal Interference Drive Divergent Evolutionary Pathways in Phage Qβ.International journal of molecular sciences · 2025Article
- Article
- Isolation and Genomic Analysis ofAntibiotics (Basel, Switzerland) · 2025Article
- Isolation and Characterization of a NovelAntibiotics (Basel, Switzerland) · 2024Article
- Characterization and Genome Analyses of the Novel Phages P2 and vB_AhydM-H1 TargetingPHAGE (New Rochelle, N.Y.) · 2024Article
- The dynamics of phage predation on a microcolony.Biophysical journal · 2024Article
- Characterization and genomic analysis of a lyticFrontiers in microbiology · 2024Article
- Automating Predictive Phage Therapy Pharmacology.Antibiotics (Basel, Switzerland) · 2023Review
- Genome characterization of the novel lytic phage vB_AbaAut_ChT04 and the antimicrobial activity of its lysin peptide against Acinetobacter baumannii isolates from different time periods.Archives of virology · 2023Article
- Characterization and biocontrol efficacy of lytic phage (KPP-1) that infects multidrug resistant Klebsiella variicola.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- New Bacteriophages Members of thePHAGE (New Rochelle, N.Y.) · 2023Article
- The balance between fitness advantages and costs drives adaptation of bacteriophage Qβ to changes in host density at different temperatures.Frontiers in microbiology · 2023Article
- Effects of Ocean Warming on the Underexplored Members of the Coral Microbiome.Integrative and comparative biology · 2022Review
- In Vitro Techniques and Measurements of Phage Characteristics That Are Important for Phage Therapy Success.Viruses · 2022Review
- Isolation and Molecular Characterization of a Novel Lytic Bacteriophage That Inactivates MDRPharmaceutics · 2022Article
- Phage-Host Interaction Analysis by Flow Cytometry Allows for Rapid and Efficient Screening of Phages.Antibiotics (Basel, Switzerland) · 2022Article
- Phenotypic flux: The role of physiology in explaining the conundrum of bacterial persistence amid phage attack.Virus evolution · 2022Review
- Challenges and innovations in treating chronic and acute wound infections: from basic science to clinical practice.Burns & trauma · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The use of bacteriophages as antibacterial agents is being actively researched on a global scale. Typically, the phages used are isolated from the wild by plating on the bacteria of interest, and a far larger set of candidate phages is often available than can be used in any application. When an excess of phages is available, how should the best phages be identified? Here we consider phage-bacterial population dynamics as a basis for evaluating and predicting phage success. A central question is whether the innate dynamical properties of phages are the determinants of success, or instead, whether extrinsic, indirect effects can be responsible. We address the dynamical perspective, motivated in part by the absence of dynamics in previously suggested principles of phage therapy. Current mathematical models of bacterial-phage dynamics do not capture the realities of in vivo dynamics, nor is this likely to change, but they do give insight to qualitative properties that may be generalizable. In particular, phage adsorption rate may be critical to treatment success, so understanding the effects of the in vivo environment on host availability may allow prediction of useful phages prior to in vivo experimentation. Principles for predicting efficacy may be derived by developing a greater understanding of the in vivo system, or such principles could be determined empirically by comparing phages with known differences in their dynamic properties. The comparative approach promises to be a powerful method of discovering the key to phage success. We offer five recommendations for future study: (i) compare phages differing in treatment efficacy to identify the phage properties associated with success, (ii) assay dynamics in vivo, (iii) understand mechanisms of bacterial escape from phages, (iv) test phages in model infections that are relevant to the intended clinical applications, and (v) develop new classes of models for phage growth in spatially heterogeneous environments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.